The Amsterdam-based biotech company, Caelus Health, is pioneering a new class of Microbiome Therapeutics. Their innovative products aim to enhance insulin sensitivity, delay the onset of Type 2 Diabetes, and reduce the risk of cardiovascular disorders in overweight individuals with an increased diabetes risk. By leveraging the power of the microbiome, Caelus Health provides premium drugs for improved health outcomes.